NASDAQ
15.06.26 | 21:50
1,650 US-Dollar
+4,43 % +0,070
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.06. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | BeyondSpring names new CEO, CFO as founder shifts to chairman role | 1 | Investing.com | ||
| 04.06. | BeyondSpring, Inc.: BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value | 179 | GlobeNewswire (Europe) | Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer - a structure designed to give... ► Artikel lesen | |
| BEYONDSPRING Aktie jetzt für 0€ handeln | |||||
| 02.06. | BeyondSpring reports phase 2 lung cancer trial results at ASCO | 1 | Investing.com | ||
| 02.06. | BeyondSpring, Inc.: BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor ... | 1 | GlobeNewswire (USA) | ||
| 18.05. | BeyondSpring, Inc.: BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 13.05. | BeyondSpring Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.05. | BeyondSpring Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.04. | BeyondSpring, Inc.: BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs | 1 | GlobeNewswire (USA) | ||
| 30.03. | BeyondSpring, Inc.: BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 | 3 | GlobeNewswire (USA) | ||
| 25.03. | BeyondSpring, Inc.: BeyondSpring Files 2025 Annual Report on Form 10-K | 1 | GlobeNewswire (USA) | ||
| 25.03. | BeyondSpring Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | BeyondSpring, Inc.: BeyondSpring Reports 2025 Year-End Financial Results | 147 | GlobeNewswire (Europe) | Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care... ► Artikel lesen | |
| 25.03. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.12.25 | BeyondSpring, Inc.: BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC | 436 | GlobeNewswire (Europe) | In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 31,765 | -0,67 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 41,740 | -9,52 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| TANGO THERAPEUTICS | 32,470 | +4,88 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,200 | +1,43 % | Summit Therapeutics: CEO-Aktienkauf sorgt für Kursplus | ||
| APOGEE THERAPEUTICS | 86,26 | -2,34 % | Apogee Therapeutics, Inc. - 8-K, Current Report | ||
| ABSCI | 7,170 | +5,36 % | Guggenheim hebt Kursziel für Absci auf 15 US-Dollar an - Potenzial durch Haarwuchsmittel | ||
| PRAXIS PRECISION MEDICINES | 265,27 | -0,67 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 3,265 | +3,49 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| IMMUNOVANT | 33,210 | -1,22 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 15,250 | +4,45 % | H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights | ||
| ERASCA | 14,300 | +1,92 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 42,960 | +0,07 % | H.C. Wainwright cuts Structure Therapeutics stock price target to $70 | ||
| BEAM THERAPEUTICS | 30,880 | +6,41 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 33,390 | +0,94 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,950 | +1,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) |
Das Unternehmen BEYONDSPRING INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,650 Euro und damit +4,43 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BEYONDSPRING INC finden Sie auf Wallstreet Online.